VolitionRx Secures ~$5.5M In Belgium Regional Government Financing From Wallonie Entreprendre
Portfolio Pulse from Benzinga Newsdesk
VolitionRx Limited (NYSE:VNRX) has received approximately $5.5 million in financing from Wallonie Entreprendre S.A. in Belgium. The funds will support the development of Volition's Nu.Q® product portfolio, particularly the clinical and regulatory program for Nu.Q® NETs aimed at early disease diagnosis such as sepsis. The financing includes a Euro 2.5 million unsecured loan and a private placement of shares. The loan has an 8% interest rate and matures on December 31, 2028, with tranche availability until June 30, 2025.
December 05, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VolitionRx Limited has secured approximately $5.5 million in financing to further develop its Nu.Q® product portfolio, which could positively impact the company's research and development capabilities.
The financing from Wallonie Entreprendre S.A. is a significant capital infusion for VolitionRx, which will likely be used to accelerate the development of its Nu.Q® product line. This could lead to advancements in early disease diagnosis, potentially increasing the company's value and investor interest in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100